Omada Health (NASDAQ:OMDA) CAO Sells $120,093.48 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CAO Craig Gracey sold 6,894 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $17.42, for a total value of $120,093.48. Following the completion of the transaction, the chief accounting officer owned 9,191 shares of the company’s stock, valued at $160,107.22. The trade was a 42.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Omada Health Price Performance

Shares of NASDAQ OMDA traded down $0.24 during trading hours on Tuesday, reaching $17.09. The stock had a trading volume of 729,778 shares, compared to its average volume of 1,213,043. The business’s fifty day moving average is $15.45 and its two-hundred day moving average is $14.80. The company has a market cap of $1.02 billion and a price-to-earnings ratio of -63.30. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $26.92.

Omada Health (NASDAQ:OMDA) last issued its earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $78.05 million during the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. Sell-side analysts forecast that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on OMDA. Barclays upped their price target on Omada Health from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Canaccord Genuity Group set a $24.00 price target on Omada Health in a research report on Friday, May 8th. JPMorgan Chase & Co. lowered their price target on Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Wall Street Zen cut Omada Health from a “buy” rating to a “hold” rating in a research report on Saturday, May 30th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a research report on Friday, May 8th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.91.

Institutional Trading of Omada Health

Several large investors have recently made changes to their positions in OMDA. Quarry LP bought a new stake in shares of Omada Health during the fourth quarter worth $29,000. TD Waterhouse Canada Inc. acquired a new stake in Omada Health in the fourth quarter worth about $32,000. Raymond James Financial Inc. acquired a new stake in Omada Health in the second quarter worth about $32,000. Inlight Wealth Management LLC acquired a new stake in Omada Health in the fourth quarter worth about $45,000. Finally, Strs Ohio increased its position in Omada Health by 151.0% in the fourth quarter. Strs Ohio now owns 4,267 shares of the company’s stock worth $67,000 after purchasing an additional 2,567 shares during the period.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.